GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists
about
Rat Ultrasonic Vocalizations and Behavioral Neuropharmacology: From the Screening of Drugs to the Study of DiseaseA brief history of the development of antidepressant drugs: from monoamines to glutamateAffective preclinical modeling of psychiatric disorders: taking imbalanced primal emotional feelings of animals seriously in our search for novel antidepressantsComparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depressionRapastinel (GLYX-13) has therapeutic potential for the treatment of post-traumatic stress disorder: Characterization of a NMDA receptor-mediated metaplasticity process in the medial prefrontal cortex of rats.GLYX-13, a NMDA Receptor Glycine-Site Functional Partial Agonist, Attenuates Cerebral Ischemia Injury In Vivo and Vitro by Differential Modulations of NMDA Receptors Subunit Components at Different Post-Ischemia Stage in MiceThe IGF-derived tripeptide Gly-Pro-Glu is a weak NMDA receptor agonistNew targets for rapid antidepressant action.The Development of Rapastinel (Formerly GLYX-13); A Rapid Acting and Long Lasting Antidepressant.Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression.PI3K/AKT/mTOR signaling-mediated neuropeptide VGF in the hippocampus of mice is involved in the rapid onset antidepressant-like effects of GLYX-13.Differential Effects of D-Cycloserine and ACBC at NMDA Receptors in the Rat Entorhinal Cortex Are Related to Efficacy at the Co-Agonist Binding Site.Ketamine Strengthens CRF-Activated Amygdala Inputs to Basal Dendrites in mPFC Layer V Pyramidal Cells in the Prelimbic but not Infralimbic Subregion, A Key Suppressor of Stress ResponsesGLYX-13 (rapastinel) ameliorates subchronic phencyclidine- and ketamine-induced declarative memory deficits in mice.Novel Glutamatergic Treatments for Severe Mood Disorders.ON or OFF?: Modulating the N-Methyl-D-Aspartate Receptor in Major Depression.Therapeutic Modulation of Glutamate Receptors in Major Depressive DisorderSynaptic Plasticity, Metaplasticity and Depression.Effects of sarcosine and N, N-dimethylglycine on NMDA receptor-mediated excitatory field potentials.Modulation of the activity of N-methyl-d-aspartate receptors as a novel treatment option for depression: current clinical evidence and therapeutic potential of rapastinel (GLYX-13).NMDA antagonists under investigation for the treatment of major depressive disorder.Novel investigational therapeutics for panic disorder.New hypothesis and treatment targets of depression: an integrated view of key findings.Glutamatergic Mechanisms Associated with Seizures and Epilepsy.Antibodies as a source of anti-infective peptides: an update.Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder.Treating to target in major depressive disorder: response to remission to functional recovery.Strategies to mitigate dissociative and psychotomimetic effects of ketamine in the treatment of major depressive episodes: a narrative review.D-cycloserine in Schizophrenia: New Strategies for Improving Clinical Outcomes by Enhancing Plasticity.Synaptic alterations associated with depression and schizophrenia: potential as a therapeutic target.Mood Therapeutics: Novel Pharmacological Approaches for Treating DepressionRapid-onset antidepressant action of ketamine: potential revolution in understanding and future pharmacologic treatment of depression.The long-lasting antidepressant effects of rapastinel (GLYX-13) are associated with a metaplasticity process in the medial prefrontal cortex and hippocampus.Cryo-EM structures of the triheteromeric NMDA receptor and its allosteric modulation.GluN2B N-methyl-D-aspartate receptor and excitatory amino acid transporter 3 are upregulated in primary sensory neurons after 7 days of morphine administration in rats: implication for opiate-induced hyperalgesia.Comparison of the Psychopharmacological Effects of Tiletamine and Ketamine in Rodents.Effect of a Novel NMDA Receptor Modulator, Rapastinel (Formerly GLYX-13), in OCD: Proof of Concept.Ionotropic glutamate receptors activate cell signaling in response to glutamate in Schwann cells.Engaging homeostatic plasticity to treat depression.Betaine enhances antidepressant-like, but blocks psychotomimetic effects of ketamine in mice.
P2860
Q26786512-E743845A-B9DD-4C84-8D90-46324C93F7BDQ27028050-CB421CCA-0F1D-4BBD-881F-1E69BF1B1F25Q28068011-A079200F-B0B1-43B7-9E49-6279EC06C87FQ28277636-6C13240D-5E77-4E3D-9351-8C387483BB32Q30695515-6F486FE7-8408-47B5-AAAE-E9240A1FD367Q33780749-3A2A480E-67BB-4502-A5C4-E861F4E8B6DEQ34063244-683C5FA2-22F9-419C-B5C7-D0899EF3472BQ34507177-303B61AE-A14C-4679-B7F0-E73C6AD60C8DQ34519141-381F8A22-712A-4A09-8764-763AAE2EEE3AQ34551188-A78D48DE-88D9-44C8-96DC-B52CA4914BFCQ35224315-A6B76B95-BE35-4E03-B52C-1B343E0730A7Q35699606-63709032-4543-4D9C-80D7-ED527D1C76F9Q36184922-1FDA4312-F2D9-4D99-BBCE-64D0E1857FC2Q36486035-91CABEBD-833D-4EF9-BCFE-AB00EF0039A5Q36498659-D64015B6-D52F-4578-AC0E-879F27AF0D8AQ37583961-ABDFD600-782D-4DFB-B4E8-4B259E7776B1Q37668014-E2571806-FC2A-4093-AAB2-D8560F5FC77EQ37668039-E4321BEF-346A-466B-91C0-81750290128BQ37673343-93A03F8C-3B9F-437B-92B7-E3A00300852FQ37741989-52717559-84BB-4409-AE2C-7D9D3C537FEBQ38211107-DEB53CF1-55B3-4780-91D5-DFE497D333D1Q38300166-F46EF063-7722-4E18-9D4A-63AAA4D504C1Q38313116-B3AEA0BA-2D39-433A-8C00-25ACB6F12715Q38535033-BC0510D1-B751-49AE-9095-851EBF69534DQ38539513-8833FA3B-1FC6-410A-9F09-3D9069C43656Q38543238-6DEF0307-16E5-4015-9A26-1695B25943A4Q38673546-1A6D4D8B-1CC3-4946-8079-177DC83DA41FQ38692317-84B78F70-D72F-42C2-8957-F16085920A63Q38750121-8E80D8F2-F198-454C-ACE9-261407F8A71CQ38831859-4E5FC80C-73FD-4EB1-8782-CF64F59D5813Q38990885-D2F7591D-A2E4-4EFC-9BDE-D561E3E02ADEQ39067664-8C3BD6F3-5002-4594-8E2A-EACFB88E2064Q40569480-9437F6EF-FCD9-41A5-B540-BE801564CB93Q41502069-BC912469-4782-4DA2-B312-0D77FBED8726Q41868656-38ACE727-B4F4-4306-BA12-F2FF8A5F2D2BQ42359901-2E750E24-3AE4-4886-B030-32093CBD30A1Q44585637-EB0AC854-8DBA-4541-91BF-494AE9BB01A8Q46176330-DA54629E-B5A3-446B-A4C8-006B92065684Q47406465-2EA933CA-13F9-4CBA-AD7A-1DCE0E93FF21Q47414662-1E441CF6-5F45-4498-A29F-5D22A810A0B8
P2860
GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
GLYX-13, an NMDA receptor glyc ...... s of NMDA receptor antagonists
@ast
GLYX-13, an NMDA receptor glyc ...... s of NMDA receptor antagonists
@en
GLYX-13, an NMDA receptor glyc ...... s of NMDA receptor antagonists
@nl
type
label
GLYX-13, an NMDA receptor glyc ...... s of NMDA receptor antagonists
@ast
GLYX-13, an NMDA receptor glyc ...... s of NMDA receptor antagonists
@en
GLYX-13, an NMDA receptor glyc ...... s of NMDA receptor antagonists
@nl
prefLabel
GLYX-13, an NMDA receptor glyc ...... s of NMDA receptor antagonists
@ast
GLYX-13, an NMDA receptor glyc ...... s of NMDA receptor antagonists
@en
GLYX-13, an NMDA receptor glyc ...... s of NMDA receptor antagonists
@nl
P2093
P2860
P921
P3181
P1476
GLYX-13, an NMDA receptor glyc ...... s of NMDA receptor antagonists
@en
P2093
J David Leander
Jeffrey S Burgdorf
Joseph R Moskal
Patric K Stanton
Roger A Kroes
Ronald Burch
P2860
P304
P3181
P356
10.1517/13543784.2014.852536
P407
P577
2013-11-20T00:00:00Z